Blood Screening Market - Global Forecast 2025-2032

The blood screening market is evolving rapidly as healthcare providers and regulators prioritize innovation, reliability, and cost efficiency for early disease detection and patient safety. In an environment shaped by new technologies, changing clinical needs, and shifting policy frameworks, senior decision-makers face complex choices about investment, deployment, and partnership.

Market Snapshot: Blood Screening Market Overview

The blood screening market grew from USD 5.31 billion in 2024 to USD 5.79 billion in 2025. It is expected to continue expanding at a CAGR of 9.06%, reaching USD 10.64 billion by 2032. Growing public health initiatives, strengthened regulatory standards, and increasing demand for reliable blood safety measures are the primary growth drivers.

Scope & Segmentation: Strategic Blood Screening Market Breakdown

• Test Types: Hepatitis B Screening, Hepatitis C Screening, HIV Screening, Syphilis Screening
• Technologies: Chemiluminescence, Flow Cytometry, Immunoassays (including Chemiluminescence Immunoassay, Enzyme Linked Immunosorbent Assay, Radioimmunoassay), Molecular Diagnostics (Isothermal Amplification, Next Generation Sequencing, Polymerase Chain Reaction)
• End Users: Blood Banks, Clinics, Diagnostic Laboratories, Hospitals
• Sample Types: Plasma, Serum, Whole Blood
• Testing Modes: Lab Based, Point Of Care

• Region Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Key Companies: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., Grifols, S.A., Bio-Rad Laboratories, Inc., Ortho Clinical Diagnostics, Inc., Hologic, Inc., Terumo BCT, Inc.

Key Takeaways for Senior Decision-Makers

• Blood screening remains essential for healthcare systems working to prevent the spread of infectious diseases and protect transfusion recipients.
• Technological advancements, such as high-throughput molecular diagnostics and multiplexed immunoassays, are increasing testing efficiency and expanding analytical capabilities for laboratories.
• Diversification of supply chains and collaboration with regional manufacturers enable faster, more resilient responses to regulatory and policy changes.
• Digital integration—including laboratory information management systems and AI-powered analytics—optimizes workflow, streamlines operations, and minimizes quality risks.
• Collaboration between diagnostic companies, regulatory bodies, and healthcare providers is facilitating harmonization of standards and faster adoption of new platforms.
• End-user needs are evolving, with blood banks and hospitals prioritizing automation and throughput, while clinics seek rapid, adaptable, point-of-care solutions.

Tariff Impact on Blood Screening Value Chains

The introduction of new tariffs in 2025 on diagnostic equipment and consumables by the United States prompted major manufacturers to rethink global supply strategies. Companies have diversified supplier networks and regional production, while laboratories improved inventory practices and adopted predictive analytics to offset increased costs. This context highlights the importance of proactive supply chain management in sustaining operational efficiency and affordability for screening services.

Methodology & Data Sources

This report draws on primary interviews with laboratory leaders, clinicians, and sector experts, as well as a thorough review of industry publications, regulatory guidelines, and company disclosures. Analysis combines qualitative insights with quantitative modeling, reinforced by triangulation and validation to ensure robust, actionable findings for stakeholders.

Why This Report Matters

• Provides senior decision-makers with segmented analysis of technologies, sample types, and end-user requirements to guide investment planning.
• Identifies tariff and regulatory influences to inform proactive risk mitigation and strategic supply chain design.
• Supports long-term growth strategies by illuminating regional dynamics, emerging partnerships, and actionable innovation opportunities in blood screening.

Conclusion

A dynamic regulatory and technological environment continues to reshape the blood screening market. Leaders who prioritize agility, nuanced supply strategies, and collaboration will secure optimal positioning as demand for reliable, efficient diagnostics grows worldwide.